Expression of resistance-nodulation-cell-division efflux pumps in commonly used Burkholderia pseudomallei strains and clinical isolates from northern Australia

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 102, Issue SUPPL. 1, 2008, Pages

  Kumar, Ayush ^a   Mayo, Mark ^b   Trunck, Lily A ^a   Cheng, Allen C ^b   Currie, Bart J ^b   Schweizer, Herbert P ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

Antibiotic resistance; Burkholderia pseudomallei; Efflux pumps; Melioidosis; Polymerase chain reaction; Resistance nodulation cell division

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL PROTEIN; BACTERIAL RNA; CEFTAZIDIME; DOXYCYCLINE; MEROPENEM; MESSENGER RNA; MICROORGANISM PROTEIN; PROTEIN AMRAB OPRA; PROTEIN BPEAB OPRB; PROTEIN BPEEF OPRC; RESISTANCE NODULATION CELL DIVISION EFFLUX PUMP; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; AUSTRALIA; BACTERIAL CELL; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; BURKHOLDERIA PSEUDOMALLEI; CELL GROWTH; CONTROLLED STUDY; MICROBIAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AUSTRALIA; BACTERIAL OUTER MEMBRANE PROTEINS; BURKHOLDERIA PSEUDOMALLEI; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; OPERON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRULENCE FACTORS;

BACTERIA (MICROORGANISMS); BURKHOLDERIA PSEUDOMALLEI;

EID: 58049176488     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(08)70032-4     Document Type: Article

References (22)

1. Cheng A.C., and Currie B.J. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 18 (2005) 383-416
2. Wiersinga W.J., van der Poll T., White N.J., Day N.P., and Peacock S.J. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol 4 (2006) 272-282
3. Dance D.A., Wuthiekanun V., Chaowagul W., and White N.J. The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J Antimicrob Chemother 24 (1989) 295-309
4. Jenney A.W., Lum G., Fisher D.A., and Currie B.J. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int J Antimicrob Agents 17 (2001) 109-113
5. Ashdown L.R., and Currie B.J. Melioidosis: when in doubt leave the quinolone alone!. Med J Aust 157 (1992) 427-428
6. Chaowagul W., Suputtamongkul Y., Smith M.D., and White N.J. Oral fluoroquinolones for maintenance treatment of melioidosis. Trans R Soc Trop Med Hyg 91 (1997) 599-601
7. Wuthiekanun V., and Peacock S.J. Management of melioidosis. Expert Rev Anti Infect Ther 4 (2006) 445-455
8. Kumar A., and Schweizer H.P. Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv Drug Deliv Rev 57 (2005) 1486-1513
9. Piliouras P., Ulett G.C., Ashurst-Smith C., Hirst R.G., and Norton R.E. A comparison of antibiotic susceptibility testing methods of cotrimoxazole with Burkholderia pseudomallei. Int J Antimicrob Agents 19 (2002) 427-429
10. Moore R.A., DeShazer D., Reckseidler S., Weissman A., and Woods D.E. Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob Agents Chemother 43 (1999) 465-470
11. Chan Y.Y., Tan T.M.C., Ong Y.M., and Chua K.L. BpeAB-OprB, a multidrug efflux pump in Burkholderia pseudomallei. Antimicrob Agents Chemother 48 (2004) 1128-1135
12. Kumar A., Chua K.-L., and Schweizer H.P. Method for regulated expression of single-copy efflux pump genes in a surrogate Pseudomonas aeruginosa strain: identification of the BpeEF-OprC chloramphenicol and trimethoprim efflux pump of Burkholderia pseudomallei 1026b. Antimicrob Agents Chemother 50 (2006) 3460-3463
13. Stover C.K., Pham X.-Q., Erwin A.L., Mizoguchi S.D., Warrener P., Hickey M.J., et al. Complete genome sequence of Pseudomonas aeruginosa, an opportunistic pathogen. Nature 406 (2000) 959-964
14. Fralick J.A. Evidence that TolC is required for functioning of the Mar/AcrAB efflux pump of Escherichia coli. J Bacteriol 178 (1996) 5803-5805
15. Chuanchuen R., Murata T., Gotoh N., and Schweizer H.P. Substrate-dependent utilization of OprM or OpmH by the Pseudomonas aeruginosa MexJK efflux pump. Antimicrob Agents Chemother 49 (2005) 2133-2136
16. Jo J.T.H., Brinkman F.S., and Hancock R. Aminoglycoside efflux in Pseudomonas aeruginosa: involvement of novel outer membrane proteins. Antimicrob Agents Chemother 47 (2003) 1101-1111
17. Li X.Z., and Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs 64 (2004) 159-204
18. Clinical and Laboratory Standards Institute. M7-A7, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. (2006), Wayne, PA
19. Chan Y.Y., and Chua K.L. The Burkholderia pseudomallei BpeAB-OprB efflux pump: expression and impact on quorum sensing and virulence. J Bacteriol 187 (2005) 4707-4719
20. Chan Y.Y., Bian H.S., Tan T.M., Mattmann M.E., Geske G.D., Igarashi J., et al. Control of quorum sensing by a Burkholderia pseudomallei multidrug efflux pump. J Bacteriol 189 (2007) 4320-4324
21. Li X., Zolli-Juran M., Cechetto J.D., Daigle D.M., Wright G.D., and Brown E.D. Multicopy suppressors for novel antibacterial compounds reveal targets and drug efflux susceptibility. Chem Biol 11 (2004) 1423-1430
22. Lomovskaya O., and Bostian K.A. Practical applications and feasibility of efflux pump inhibitors in the clinic - a vision for applied use. Biochem Pharmacol 71 (2006) 910-918